SCHEMBL3404304

SCHEMBL3404304

CCN(CC)CCN(C)C(=O)c1sc(-c2cccc(Cl)c2)nc1C

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.61
TRPM8 Q7Z2W7 2/20 0.52
HTR2C P28335 3/20 0.47
ALDH1A1 P00352 4/20 0.44
MAPT P10636 3/20 0.44
MEN1 O00255 1/20 0.44
SLC6A7 Q99884 1/20 0.43
MAPK1 P28482 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
GAA P10253 2/20 0.41
HPGD P15428 1/20 0.41
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FFAR1 O14842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3399741 0.89 TRPM8 (0.50) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3404493 0.89 KMT2A (0.44) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3403618 0.87 TRPM8 (0.48) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3400862 0.87 HTR2C (0.47) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3398358 0.86 KMT2A (0.48) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3404127 0.86 HTR2C (0.49) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3403876 0.86 KMT2A (0.45) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3396808 0.85 KMT2A (0.45) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3402390 0.85 HTR2C (0.46) KMT2ATRPM8HTR2CALDH1A1MAPT
SCHEMBL3404513 0.85 HTR2C (0.46) KMT2ATRPM8HTR2CALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 KMT2A 890/4885TRPM8 455/4885HTR2C 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.